Product Revenue, Net was Biogen’s largest product and service line in fiscal 2025, bringing in $7.12B of $9.71B (73%).
| Product and Service | FY 2016 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | $7.99B | $7.25B | $7.21B | $7.12B | ||||
| Product, Net | — | — | — | — | ||||
| Subtotal: Multiple Sclerosis | — | — | — | — | ||||
| Subtotal: Ms | — | — | — | — | ||||
| Ms Product Revenues | — | — | — | — | ||||
| Total Fumarate | — | — | — | — | ||||
| Fumarate | — | — | — | — | ||||
| Revenue From Anti-Cd20 Therapeutic Programs | $1.70B | $1.69B | $1.75B | $1.86B | ||||
| Revenues From Anti-Cd20 Therapeutic Programs | — | — | — | — | ||||
| Total Interferon | — | — | — | — | ||||
| Interferon | — | — | — | — | ||||
| Tysabri | — | — | — | — | ||||
| Subtotal: Biosimilars | — | — | — | — | ||||
| Spinraza | — | — | — | — | ||||
| Tecfidera | — | — | — | — | ||||
| Contract Manufacturing, Royalty & Other Revenue | $485.10M | $899.30M | $652.60M | $732.90M | ||||
| Avonex | — | — | — | — | ||||
| Subtotal: Rare Disease | — | — | — | — | ||||
| Benepali | — | — | — | — | ||||
| Eloctate | — | — | — | — | ||||
| Vumerity | — | — | — | — | ||||
| Alprolix | — | — | — | — | ||||
| Imraldi | — | — | — | — | ||||
| Plegridy | — | — | — | — | ||||
| Fampyra | — | — | — | — | ||||
| Flixabi | — | — | — | — | ||||
| Fumaderm | — | — | — | — | ||||
| Other | — | — | — | — | ||||
| Total | $10.17B | $9.84B | $9.62B | $9.71B |
Biogen brought in $9.71B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 1.0% from $9.62B in fiscal 2024. Product Revenue, Net was the largest at $7.12B (73.3%), ahead of Revenue From Anti-Cd20 Therapeutic Programs at $1.86B (19.2%) and Contract Manufacturing, Royalty & Other Revenue at $732.90M (7.5%).
Compared with fiscal 2024, Contract Manufacturing, Royalty & Other Revenue grew fastest, up 12.3% to $732.90M, while Product Revenue, Net fell the most, down 1.3% to $7.12B. From fiscal 2022 to 2025, combined revenue from these lines fell from $10.17B to $9.71B, a compound annual decline of 1.5%. Product Revenue, Net's share of the total fell from 78.5% to 73.3%.
United States was Biogen’s largest region in fiscal 2025, bringing in $5.74B of $9.71B (59%).
| Geography | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| United States | $5.53B | $5.43B | $5.31B | $5.74B |
| Europe | $2.41B | $2.14B | $2.17B | $1.88B |
| Germany | $926.20M | $868.00M | $955.60M | $853.00M |
| Asia | $719.70M | $863.40M | $624.10M | $726.50M |
| Segment Geographical Groups Of Countries Group Other | $582.90M | $531.20M | $557.90M | $511.20M |
| Total | $10.17B | $9.84B | $9.62B | $9.71B |
Biogen brought in $9.71B from its five regions in fiscal 2025, the year ended December 31, 2025. That was up 1.0% from $9.62B in fiscal 2024. United States was the largest at $5.74B (59.1%), ahead of Europe at $1.88B (19.4%) and Germany at $853.00M (8.8%). The other two regions brought in $1.24B combined.
Compared with fiscal 2024, Asia grew fastest, up 16.4% to $726.50M, while Europe fell the most, down 13.3% to $1.88B. From fiscal 2022 to 2025, combined revenue from these regions fell from $10.17B to $9.71B, a compound annual decline of 1.5%. United States' share of the total rose from 54.4% to 59.1%.
Biogen (BIIB) reports its revenue by product and service and by geography. In fiscal 2025, Product Revenue, Net was its largest product and service line, bringing in $7.12B (73.3% of the total), followed by Revenue From Anti-Cd20 Therapeutic Programs at $1.86B (19.2%).
Product Revenue, Net was Biogen's largest product and service line in fiscal 2025, bringing in $7.12B, or 73.3% of the $9.71B total across its three product and service lines.
United States was Biogen's largest region in fiscal 2025, bringing in $5.74B, or 59.1% of the $9.71B total across its five regions.
Among Biogen's product and service lines that make up at least 2% of revenue, Contract Manufacturing, Royalty & Other Revenue grew fastest in fiscal 2025, up 12.3% from $652.60M to $732.90M.
Every figure comes from Biogen's annual financial filings, as reported. Each line keeps the name Biogen gives it, and years follow its fiscal calendar.
Biogen's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.